Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

March 31, 2013

Conditions
Colorectal Carcinoma
Interventions
DRUG

Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion

Trial Locations (1)

K1H 8L6

Ottawa Hospital and Research Institute (OHRI), Ottawa

Sponsors
All Listed Sponsors
lead

Jennerex Biotherapeutics

INDUSTRY

NCT01329809 - Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors | Biotech Hunter | Biotech Hunter